Salute e Benessere
Clostridioides difficile Infection Market Forecasts by DelveInsight Signal Groundbreaking Growth at a CAGR of 13.5% in the 7MM during the Forecast Period (2025-2034)
Discover the CDI new treatment @
Advanced age, frequent hospital exposure, comorbidities, and immunosuppression are major risk factors for CDI. Global population aging and increased hospital/long-term care use concentrate vulnerable patients, thereby enlarging the addressable CDI market. According to DelveInsight analysis, in 2024, the incidence of CDI in the US was estimated at approximately in individuals aged 65 years and older.
With due to the rise of antimicrobial resistance, there is a clear need for . While current therapies reduce recurrence, a significant opportunity exists to expand , including CDI vaccines, which hold considerable clinical and economic promise despite the limited number of candidates currently in development.
Ibezapolstat demonstrates a dual benefit of clinical efficacy comparable to that of standard-of-care antibiotics, while preserving and positively modulating the gut microbiome — an increasingly significant advantage as microbiome restoration therapies, such as fecal microbiota transplantation and live biotherapeutics, gain traction in managing recurrent CDI by addressing underlying dysbiosis.
The CDI pipeline includes several drugs in mid- to late-stage development that are anticipated to gain approval soon. The evolving landscape features a broad spectrum of therapeutic options, such as (Mikrobiomik), (Vedanta Biosciences), and (Lumen Bioscience), among others. The anticipated launch of these therapies is likely to drive further positive momentum in the market.
infection continues to pose a major public health burden globally, particularly within healthcare environments. Although diagnostic and treatment approaches have progressed, the CDI market still faces substantial therapeutic challenges, most notably the high recurrence rate, which impacts 25–45% of patients depending on disease severity and recurrence history. Over the past decade, treatment options have evolved; once dominated by , the standard of care has shifted toward fidaxomicin (approved in 2011) due to its targeted, narrow-spectrum activity.
Key therapies currently shaping the CDI treatment space include , and . In a notable development, Merck withdrew from the market in January 2025 , signaling a shift in the treatment landscape. ZINPLAVA, approved by the FDA in October 2016 , was introduced as a monoclonal antibody targeting toxin B, designed to prevent recurrent Clostridium difficile infection (rCDI) in high-risk adults. (fidaxomicin), initially approved in 2011 for adults with CDI, extended its label in 2020 to include children as young as 6 months, solidifying its role as a frontline treatment.
Fecal microbiota transplantation (FMT), previously limited to investigational use, has since become a regulated therapeutic approach. While off-label use in the US began around 2008 to prevent recurrent CDI, challenges such as variability in spore composition due to donor differences remain. Nevertheless, leading guidelines in the US and Europe recommend FMT after the second recurrence. Recently, two FDA-approved FMT-based treatments, (by Seres Therapeutics and Nestlé) and (by Ferring Pharmaceuticals), have emerged as approved preventive therapies for rCDI.
REBYOTA, the first FDA-approved FMT product (approved in 2022), is rectally administered and, despite its less convenient route, is widely used in institutions for its affordability, single-dose format, and first-mover advantage. In contrast, VOWST is an oral, microbiota-based live biotherapeutic product (LBP) that has gained substantial market traction due to its convenient administration and proven efficacy.
To know more about FDA-approved drugs for CDI, visit @
The CDI pipeline possesses some drugs in mid- and late-stage development to be approved in the near future. The CDI drugs landscape holds a diverse range of therapeutic alternatives for treatment, including (Mikrobiomik), (Vedanta Biosciences), (Lumen Bioscience), (Acurx Pharmaceuticals), and others.
is an investigational therapy derived from faecal microbiota transplantation, offering a promising alternative to current treatments for infection. It is the first microbiota-based biologic approved in the EU, developed as Full-spectrum Purified Intestinal Microbiota (FSPIM) and formulated into lyophilized oral capsules.
In February 2025 , announced a key milestone with the European Medicines Agency (EMA) approving its Paediatric Investigation Plan (PIP) for MBK-01, targeting CDI treatment in children. Earlier, In January 2025 , the company received top recognition at the Quality Innovation Awards 2024, winning both the "Best Innovation in the Healthcare Sector" and the overall "Innovation of Innovations" award.
According to Mikrobiomik's development timeline, submission of the Clinical Trial Dossier (CTD) and Marketing Authorisation Application (MAA) for MBK-01 is planned for 2026, with a commercial launch expected in 2027.
, developed by Vedanta Biosciences, is a potential first-in-class live biotherapeutic for the prevention of recurrent CDI. It is an orally delivered, defined bacterial consortium composed of eight precisely selected strains. Unlike donor-derived products, VE303 is produced from pure clonal bacterial cell banks, resulting in a consistent powdered formulation that eliminates variability associated with donor fecal material.
The ongoing is assessing VE303's safety and efficacy in rCDI patients and is intended to support a future Biologics License Application (BLA) submission to the US FDA. VE303 was granted (ODD) in 2017 and (FTD) in 2023 by the FDA for the prevention of rCDI.
, a novel oral antibiotic under development by , belongs to a new class of DNA polymerase IIIC inhibitors. It targets specifically, while preserving beneficial gut bacteria, such as other Firmicutes and Actinobacteria, to help maintain microbiome balance.
In June 2025 , published results from its Phase IIb clinical trial in Lancet Microbe, highlighting the efficacy, safety, pharmacokinetics, and microbiome outcomes of ibezapolstat versus vancomycin in adults with CDI.
Additionally, in January 2025 , Acurx received favorable regulatory feedback from the EMA for its Phase III clinical program for ibezapolstat. The agency also confirmed the regulatory path toward a future MAA submission upon successful trial completion.
The anticipated launch of these emerging therapies are poised to transform the infection market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the infection market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about infection drugs in development @
infection is a severe gastrointestinal disease caused by toxin-producing bacteria, commonly associated with the use of antibiotics and healthcare environments. It manifests as either healthcare-associated (HA-CDI) or community-associated (CA-CDI) infections and can range in severity from mild diarrhea to severe, potentially fatal colitis. CDI poses a major public health challenge due to its high recurrence rate and the significant strain it places on healthcare systems.
Diagnostic approaches have evolved. The widespread adoption of Nucleic Acid Amplification Tests (NAATs) initially led to a rise in reported cases. However, to curb overdiagnosis, there is now a greater focus on diagnostic stewardship, with a renewed emphasis on confirming positive NAAT results using toxin Enzyme Immunoassay (EIA).
The infection epidemiology section provides insights into the historical and current infection patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The infection market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:
Download the report to understand which factors are driving infection market trends @
report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key infection companies, including among others.
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key infection companies, including among others.
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key bacteremia companies, including among others.
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/clostridioides-difficile-infection-market-forecasts-by-delveinsight-signal-groundbreaking-growth-at-a-cagr-of-13-5-in-the-7mm-during-the-forecast-period-20252034-302543478.html